Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival

[1]  N. Hu,et al.  Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer. , 2016, Cancer research.

[2]  J. Schellens,et al.  Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study , 2016, Investigational New Drugs.

[3]  L. Stein,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic Acids Res..

[4]  H. Lee,et al.  Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer , 2015, Pathobiology.

[5]  A. Ochiai,et al.  Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma , 2015, Gastric Cancer.

[6]  David I. Smith,et al.  WWOX, large common fragile site genes, and cancer , 2015, Experimental biology and medicine.

[7]  W. Chan,et al.  Global Promoter Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes in Natural Killer Cell Lymphoma , 2015, Clinical Cancer Research.

[8]  A. Bass,et al.  Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. , 2014, The Journal of clinical investigation.

[9]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[10]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[11]  C. West,et al.  FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation , 2014, Virchows Archiv.

[12]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[13]  W. Kim,et al.  Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade , 2013, Experimental & Molecular Medicine.

[14]  Xiaozhong Peng,et al.  Dok5 is involved in the signaling pathway of neurotrophin-3 against TrkC-induced apoptosis , 2013, Neuroscience Letters.

[15]  B. Dutrillaux,et al.  Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. , 2013, Cell reports.

[16]  Z. Herceg,et al.  Dependence receptor TrkC is a putative colon cancer tumor suppressor , 2013, Proceedings of the National Academy of Sciences.

[17]  H. Imamura,et al.  Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer , 2012, Clinical Cancer Research.

[18]  K. Ching,et al.  Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer , 2011, Molecular Cancer Therapeutics.

[19]  K. Chayama,et al.  Expression of platelet‐derived growth factor (PDGF)‐B and PDGF‐receptor β is associated with lymphatic metastasis in human gastric carcinoma , 2010, Cancer science.

[20]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[21]  K. Gunderson,et al.  Deletion at Fragile Sites Is a Common and Early Event in Barrett's Esophagus , 2010, Molecular Cancer Research.

[22]  Lei Shi,et al.  Downstream of tyrosine kinase/docking protein 6, as a novel substrate of tropomyosin-related kinase C receptor, is involved in neurotrophin 3-mediated neurite outgrowth in mouse cortex neurons , 2010, BMC Biology.

[23]  A. Laganà,et al.  Variability in the Incidence of miRNAs and Genes in Fragile Sites and the Role of Repeats and CpG Islands in the Distribution of Genetic Material , 2010, PloS one.

[24]  Y. Murakumo,et al.  Analysis of DOK‐6 function in downstream signaling of RET in human neuroblastoma cells , 2010, Cancer science.

[25]  W. Gerald,et al.  Identification of DOK genes as lung tumor suppressors , 2010, Nature Genetics.

[26]  P. Deloukas,et al.  Signatures of mutation and selection in the cancer genome , 2010, Nature.

[27]  Y. Yamanashi,et al.  The roles of Dok family adapters in immunoreceptor signaling , 2009, Immunological reviews.

[28]  M. Heuser,et al.  High-affinity neurotrophin receptors and ligands promote leukemogenesis. , 2009, Blood.

[29]  A. Papavassiliou,et al.  Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study , 2008, Oncogene.

[30]  W. Lewis,et al.  Prognostic significance of gastrin expression in patients undergoing R0 gastrectomy for adenocarcinoma , 2007, Gastric Cancer.

[31]  B. Kerem,et al.  FRA18C: a new aphidicolin-inducible fragile site on chromosome 18q22, possibly associated with in vivo chromosome breakage , 2007, Journal of Medical Genetics.

[32]  David I. Smith,et al.  Large common fragile site genes and cancer. , 2007, Seminars in cancer biology.

[33]  Joachim Weis,et al.  The Dark Side of the NGF Family: Neurotrophins in Neoplasias , 2006, Brain pathology.

[34]  N. Carter,et al.  Factors affecting flow karyotype resolution , 2006, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[35]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[36]  M. Vieth,et al.  Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Q. Ma,et al.  Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. , 2005, Oncology reports.

[38]  R. Crowder,et al.  Dok-6, a Novel p62 Dok Family Member, Promotes Ret-mediated Neurite Outgrowth* , 2004, Journal of Biological Chemistry.

[39]  G. Church,et al.  Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae , 2001, Nature Genetics.

[40]  D J Porteous,et al.  WWOX: A candidate tumor suppressor gene involved in multiple tumor types , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Patrik D'haeseleer,et al.  Genetic network inference: from co-expression clustering to reverse engineering , 2000, Bioinform..

[42]  J. Merchant,et al.  EGF receptor activation stimulates endogenous gastrin gene expression in canine G cells and human gastric cell cultures. , 1997, The Journal of clinical investigation.

[43]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[44]  N. Carter,et al.  Reverse chromosome painting: a method for the rapid analysis of aberrant chromosomes in clinical cytogenetics. , 1992, Journal of medical genetics.

[45]  J. Yunis,et al.  Constitutive fragile sites and cancer. , 1984, Science.

[46]  M. Kanehisa.  Post-Genome Informatics , 2000 .

[47]  Y. Matsuzawa,et al.  Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. , 1999, Gastroenterology.